Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19458 | 0.80 | TDP1 (0.42) | CYP2D6CA12CA1CA7CA14 | |
| SCHEMBL5551672 | 0.77 | CYP2D6 (0.35) | CYP2D6CA12CA1CA7CA14 | |
| SCHEMBL13819420 | 0.76 | LMNA (0.33) | CYP2D6CA1CA7NR1D1 | |
| SCHEMBL18495534 | 0.75 | TDP1 (0.44) | CA12CA1CA7CA14 | |
| SCHEMBL4338603 | 0.74 | CYP2D6 (0.34) | CYP2D6CA12CA1CA7CA14 | |
| SCHEMBL16315898 | 0.74 | CA12 (0.36) | CA12CA1CA7CA14 | |
| SCHEMBL7567960 | 0.74 | CHRM2 (0.37) | CA12CA1CA7CA14NR1D1 | |
| SCHEMBL992084 | 0.74 | TDP1 (0.58) | CA1NR1D1 | |
| SCHEMBL29484958 | 0.74 | CA14 (0.38) | CYP2D6CA12CA1CA7CA14 | |
| SCHEMBL438113 | 0.74 | TDP1 (0.58) | CA1NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142546-A1 | RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING | THE ASAN FOUNDATION (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142546-A1 | RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING | SERPINC1, F3, F11 | CYP2D6 3603/4885CA12 683/4885CA1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.